Cancer Family
Mesenchymal Cell Neoplasm
CI-CAN-00000027Explore in graph →
Non-malignant413 active trials10 approved drugs208 evidence items
- NCIt
- C7059
Loading cancer entity…
Cancer Family
CI-CAN-00000027Explore in graph →
Clinical trials
1,848 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00265798 | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02847559 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | completed | Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 |
| clinicaltrials |
| NCT07809178 | China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm(ChTTSRUIA) | not yet recruiting | — | 608 | Cheng senOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06955169 | Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment(MOMENTUM-1) | recruiting | Phase 2 | 130 | RTOG Foundation, Inc.OTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma(STELLAR-201) | recruiting | Phase 2 | 100 | ExelixisINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT00411060 | Clinical Orthopaedic Data Bank (Acute and Chronic) | recruiting | — | 10,000 | University of FloridaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | recruiting | Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | recruiting | Phase 1 / Phase 2 | 74 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma | not yet recruiting | Phase 1 / Phase 2 | 70 | SOTIO Biotech a.s.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | recruiting | Phase 2 | 124 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04890067 | Observational Study in Localized Osteosarcoma(ISG Os2Oss) | recruiting | — | 120 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03900793 | Losartan + Sunitinib in Treatment of Osteosarcoma | recruiting | Phase 1 | 41 | University of Colorado, DenverOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07227571 | Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial | recruiting | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | recruiting | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797270 | Ultrasound-Guided Emulsification Therapy in the Clinical Treatment of Subcutaneous Lipomas | not yet recruiting | N/A | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT02974127 | Multisession Radiosurgery in Large Meningiomas(MuRaLM) | completed | — | 178 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04298541 | Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05493215 | Imatinib TDM in GIST | recruiting | Phase 2 | 28 | Reema A. PatelOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02567435 | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | active not recruiting | Phase 3 | 325 | National Cancer Institute (NCI)NIH | 5 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07282470 | Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND(MIND) | active not recruiting | — | 210 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | active not recruiting | Phase 1 / Phase 2 | 62 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06389799 | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)(PERELI) | recruiting | Phase 2 | 33 | Lund University HospitalOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07261657 | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | recruiting | Early Phase 1 | 8 | Seth PollackOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07516925 | A Study of Ivonescimab in People With Leiomyosarcoma | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04044768 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | active not recruiting | Phase 2 | 52 | USWM CT, LLCINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06557512 | Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma(SRS-AIM) | recruiting | N/A | 23 | University of California, San FranciscoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07054944 | Tumor-Lymph Node Mapping(T-LyM) | not yet recruiting | — | 10 | University of RochesterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787429 | Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma(Dragonfly) | recruiting | Phase 2 | 40 | Anna RaciborskaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05235165 | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | recruiting | Phase 3 | 62 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT05304585 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | recruiting | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Aug 25, 2026 | clinicaltrials |
| NCT05867901 | A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy | suspended | — | 66 | Peking University People's HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07466316 | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | recruiting | Phase 3 | 342 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT02693990 | A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07514819 | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma | recruiting | N/A | 100 | St. Jude Children's Research HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07780019 | Microwave Ablation of Uterine Fibroids(MyoMwa) | active not recruiting | — | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)(DeFi) | completed | Phase 3 | 142 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05683041 | Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy(PALLM) | recruiting | N/A | 30 | University Hospital, GhentOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials